Merck & Co., Inc. (MRK) Stock Price: $119.60+0.08 (+0.07%)
The total return cagr for Merck & Co., Inc. (MRK) stock is 56.29% over the past 12 months. The 3 year average growth rate is 5.80% and the 5 year cagr is 13.58%. Total return includes dividends reinvested.
The closing share price for Merck & Co., Inc. (MRK) stock was $119.60 for Tuesday, June 9, 2026, up +0.07% from the previous day.
MRK Price Chart
MRK Key Metrics
See All MetricsMRK Earnings Preview
Next Earnings Date
Aug 4, 2026
56 days away
EPS Estimate
-0.15
Revenue Est.
$16.36B
Last Quarter Results
EPS
$-1.28
vs Estimate
$-1.47
Revenue
$16.29B
vs Estimate
$15.85B
MRK Analyst Ratings
Consensus Rating
Based on 27 analysts
Average Price Target
$129.74
+8.5% upside
Low
$100.00
Current
$119.60
High
$150.00
MRK Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2026 | N/A | $-1.47 | N/A | 12 |
| Q2 2026 | N/A | $2.11 | N/A | 4 |
| Q3 2026 | N/A | $2.29 | N/A | 4 |
| Q4 2026 | N/A | $2.00 | N/A | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $9.64 | N/A | 6 |
| FY 2028 | N/A | $10.69 | N/A | 3 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2026 | N/A | $15.85B | N/A | 12 |
| Q2 2026 | N/A | $16.36B | N/A | 4 |
| Q3 2026 | N/A | $17.38B | N/A | 4 |
| Q4 2026 | N/A | $16.73B | N/A | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $70.15B | N/A | 6 |
| FY 2028 | N/A | $74.90B | N/A | 3 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
MRK Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1MRK | $295.39B | $119.60 | +0.07% | +56.29% | +13.58% | +11.55% |
MRK Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis